Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00648895 · ClinicalTrials.gov registry record · Phase 3
A Study of the Effect of Nebivolol to Evaluate Its Vasodilatory Effects in Hypertensive Patients
A Phase 3 study, sponsored by Forest Laboratories.
- Completed
- Registry status
- Phase 3
- Development phase
- 12
- Enrollment target
NCT00648895 is a Phase 3 study that has completed, run by Forest Laboratories. The registered enrollment target is 12 participants.
The verdict
NCT00648895, a Phase 3 study, has completed, sponsored by Forest Laboratories.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 12 participants
- Enrollment target
Study Summary
The study is designed to compare the effects of nebivolol (10, 20, 40mg/day) with another beta blocker, extended-release metoprolol, at a range of doses. Its purpose is to study the mechanism of action of nebivolol on forearm blood flow, nitric oxide availability and other biomarkers.
Interventions
- DRUG Nebivolol
- DRUG Metoprolol ER (TM)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2007-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00648895
The ClinicalTrials.gov registry entry for NCT00648895 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Forest Laboratories, which has 145 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nebivolol is the first listed.
NCT00648895 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00648895 about?
NCT00648895 is a clinical study titled "A Study of the Effect of Nebivolol to Evaluate Its Vasodilatory Effects in Hypertensive Patients". The study is designed to compare the effects of nebivolol (10, 20, 40mg/day) with another beta blocker, extended-release metoprolol, at a range of doses. Its purpose is to study the mechanism of action of nebivolol on forearm blood flow, nitric oxide availability and other biomarkers.
What is the current status of trial NCT00648895?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 12 participants. The study started on 2007-11.
What interventions are being tested in trial NCT00648895?
The interventions under investigation include: Nebivolol (DRUG), Metoprolol ER (TM) (DRUG).
Who is sponsoring clinical trial NCT00648895?
This trial is sponsored by Forest Laboratories, which has 145 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.